The 30-second summary
- In large trials, semaglutide and tirzepatide lowered the risk of heart attack, stroke, and death, not just body weight.
- The newest 2026 data shows the heart benefit starts early, before most of the weight is lost, so it is not weight loss alone doing the work.
- This matters more for women than most guidance admits. Heart disease is the leading cause of death in women, and it is still under-diagnosed and under-treated.
Why this is bigger than another weight number
For years the headline about GLP-1 medications was the scale. Fifteen percent. Twenty percent. The numbers got the attention. The quieter finding is the one that will outlast the hype: these drugs protect the heart.
That is a different kind of claim. A smaller waist is a number you can see. A heart attack that never happens is a number you never get to count. The trials counted it for you, and the result is the strongest argument yet for taking these medications seriously as cardiac drugs, not just weight drugs.
What the trials actually found
The landmark study is SELECT. It followed more than 17,000 adults who had heart disease and obesity but not diabetes, and gave half of them semaglutide. Over roughly three years, the semaglutide group had about 20 percent fewer major cardiac events, heart attack, stroke, or death from heart disease, than the placebo group. (Lincoff et al., NEJM 2023.)
In May 2026, a head-to-head analysis from Mass General Brigham, published in Nature Medicine, put the two leading drugs side by side. Both helped. Semaglutide cut the risk of heart attack and stroke by about 18 percent against a neutral comparison drug. Tirzepatide cut the combined risk of heart attack, stroke, and death by about 13 percent against another drug in the class. (Mass General Brigham, 2026.)
The picture is consistent. Different drugs, different comparisons, same direction. The heart benefit is real.
The part that surprised the researchers
Here is the finding worth slowing down for. The protection appears to start early, before most of the weight has come off.
Work reported in May 2026 by teams at the Technical University of Munich and Harvard Medical School pointed to the same conclusion: the curves separating treated patients from untreated ones begin to spread within months, sooner than weight loss alone could explain. (ScienceDaily, May 2026.)
If weight loss were the only mechanism, the benefit would arrive slowly, in step with the pounds. It does not. That tells researchers the drug is doing something else for the heart directly, calming inflammation in blood vessels, easing the workload on the heart, improving how blood vessels relax. The weight loss helps. It is just not the whole story.
For you, the practical message is simple. The cardiac benefit is not a reward you have to earn by reaching goal weight. It starts working while you are still on the way there.
Semaglutide or tirzepatide for the heart
People want a winner. The honest answer is that both protect the heart, and they have not been tested against each other in a single trial built to settle it.
Some real-world data hints that semaglutide may have a small edge on cardiac events. Other data favours tirzepatide on weight and blood sugar. The differences are modest, and the studies are observational, which means they describe what happened in clinics rather than what a controlled experiment proved. The drug that protects your heart best is the one you can get, tolerate, afford, and stay on.
What this means for women
Cardiovascular disease is the leading cause of death in women. It is also under-recognised in women, partly because the early research was done largely in men, and partly because women's symptoms are dismissed more often.
That makes a medication with a proven heart benefit especially relevant to the women this app is built for. Many women start a GLP-1 for weight or blood sugar and discover the heart protection as a bonus they did not know to ask about. If you have a family history of heart disease, high blood pressure, or high cholesterol, it is worth raising with your prescriber, because it may change how you both weigh the decision.
The risk does not stop at menopause. It rises. The drop in oestrogen around perimenopause removes some of the natural protection younger women have, which is exactly when many women begin a GLP-1.
What this does not mean
It does not mean the drug is a substitute for the basics. Blood pressure control, not smoking, sleep, movement, and the protein and muscle work that keep you strong all still matter, and they protect the heart too.
It does not mean you should chase a higher dose for a bigger heart benefit. The trial benefits came at standard prescribed doses, under medical supervision.
And it does not mean you can ignore the warning signs. Chest pain, pressure spreading to the arm or jaw, sudden breathlessness, or a racing heart that will not settle are reasons to call emergency services, not your tracking app. In the US, call 911. In the UK, 999. In the EU, 112.
What Steady helps you do
Steady is not a cardiac monitor, and it does not pretend to be. What it does is keep the picture your prescriber actually needs in one place: your dose history, your weight trend as a steady moving average rather than a jumpy morning number, and the symptoms that come and go week to week.
When you sit down for a review and the conversation turns to your heart, the difference between a vague memory and a clean record is the difference between a guess and a plan. Steady keeps the record so the plan is easy.
Sources
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023; 389:2221-2232. NEJM
- Mass General Brigham. GLP-1 Drugs Tirzepatide and Semaglutide Provide Protection for Heart Health. 2026. Mass General Brigham
- Technical University of Munich and Harvard Medical School. Popular GLP-1 weight-loss drugs slash heart attack and stroke risk. ScienceDaily, May 2026. ScienceDaily
- Wegovy (semaglutide) Prescribing Information, cardiovascular indication. FDA. FDA label
Medical disclaimer: This article is educational, not medical advice. Decisions about heart health and medication belong with your prescriber. If you have symptoms of a heart attack or stroke, call emergency services immediately. See our full medical disclaimer.